Evidence map›Paper›PMID 40050802›Full record

ArticleMolecular cancer2025

Engineered multifunctional nanoparticles for enhanced radiation therapy: three-in-one approach for cancer treatment.

Tejaswini Appidi, Debarghya China, George-Răzvan Ștefan, Michele Moreau, Serena Mao, Esteban Velarde, Ngeh Toyang, Henry Lowe, Aravind Kumar Rengan, Kai Ding and 1 more

Abstract read
In one paragraph

Article in Molecular cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Next Generation Calcium Nanomaterials: Disrupting Tumor CaInternational journal of nanomedicine · 2026
    Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tejaswini AppidiDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. tappidi1@jh.edu.
Debarghya ChinaDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, Maryland, USA.
George-Răzvan ȘtefanCarol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Michele MoreauDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Serena MaoDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Esteban VelardeDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Ngeh ToyangFlavocure Biotech Inc, Baltimore, Maryland, USA.
Henry LoweFlavocure Biotech Inc, Baltimore, Maryland, USA.
Aravind Kumar RenganDepartment of Biomedical Engineering, Indian Institute of Technology Hyderabad, Hyderabad, India.
Kai DingDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Wilfred NgwaDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. wngwa1@jh.edu.

Funding

Biomaterial Drones for Image-Guided Drug Delivery during radiotherapyR01CA239042 · NCI · JOHNS HOPKINS UNIVERSITY · PI NGWA, WILFRED · 2019 to 2023
$3.2M
National Institutes of Health, United States R01CA239042NCI NIH HHS R01 CA239042
6 · The paper itself

Abstract

Clinical cancer treatment modalities include radiation as one of the first-line therapies used for treating almost two-thirds of cancer patients. Combinational therapy for cancer is becoming extremely popular, with multiple therapies and their pharmacological effects expected to provide a synergistic outcome. The nanotechnology-based combinational therapeutic approach is emerging as a more effective strategy, for its advantages include simultaneous loading of multiple drugs, on-demand drug delivery controlled by external or internal stimulus, targeting a particular site, and the potential to combine physical treatment modalities (like radiation, thermal therapies, etc.) with chemical interventions (like chemotherapy, immunotherapy, etc.). We report a combination of radiotherapy and chemotherapy mediated by a multifunctional lipo-polymeric hybrid nanosystem coated with gold, demonstrating the three different functionalities using a single nanosystem: a) radio sensitization, b) radiation-triggered delivery of drugs, and c) application as an X-ray/CT contrast agent. The lipo-polymeric hybrid nanoparticles, synthesized using a modified hydrogel isolation method, were loaded with a natural plant-derived anti-cancer agent "Caflanone." These nanoparticles were further subjected to in-situ reduction for a surface coating of gold, which provided enhanced radiosensitivity, radiation triggered drug delivery and X-ray/CT imaging. This approach using a multifunctional nanosystem leverages the biocompatibility of the lipo-polymeric hybrid system for the loading of drugs, precise spatiotemporal controllability of radiation for drug release, and the cytotoxicity of the plant-derived anti-cancer agent "Caflanone." A significant therapeutic efficacy in vitro against breast cancer (p = 0.0002), pancreatic cancer (p < 0.0001), and glioblastoma (p < 0.0001) was demonstrated with the combinational approach. The application of the nanosystem as an X-ray/CT contrast agent has been shown in vivo in tumor-bearing mice and the safety profile and histopathology evaluated in healthy mice showed no adverse effects. A significant increase (p = 0.01) in the survival of breast tumor-bearing mice treated with a combinational approach was also demonstrated. The engineered multifunctional nanoparticles enhanced the radiation therapy and triggered the drug release at the tumor site, triggering the action of encapsulated chemotherapeutic agents while providing image guidance.

Indexed as

Multifunctional NanoparticlesNeoplasmsAnimalsAntineoplastic AgentsCell Line, TumorCombined Modality TherapyDrug Delivery SystemsFemaleGoldHumansMiceRadiation-Sensitizing AgentsXenograft Model Antitumor AssaysAntineoplastic AgentsGoldRadiation-Sensitizing Agents

Identifiers

PMID40050802
PMCPMC11883980

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.